P1451: PRELIMINARY RESULTS FROM THE FLU/CY/ALEMTUZUMAB ARM OF THE PHASE I BALLI-01 TRIAL OF UCART22, AN ANTI-CD22 ALLOGENEIC CAR-T CELL PRODUCT, IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) CD22+ B-CELL ALL
Main Authors: | N. Jain, G. Roboz, M. Konopleva, H. Liu, G. Schiller, E. Jabbour, P. Desai, D. Whitfield, A. Haider, O. Zernovak, M. Frattini, C. Brownstein, R. Larson |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-06-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/01.HS9.0000848660.69944.40 |
Similar Items
-
P1408: UPDATED RESULTS OF THE PHASE I BALLI-01 TRIAL OF UCART22, AN ANTI-CD22 ALLOGENEIC CAR-T CELL PRODUCT, IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CD22+ B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)
by: Nicolas Boissel, et al.
Published: (2023-08-01) -
Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cells
by: Alexandra Dreyzin, et al.
Published: (2023-03-01) -
P1420: PRE-CLINICAL PROOF OF CONCEPT DEMONSTRATES ROBUST ACTIVITY OF UCART20X22 DUAL CAR T-CELLS FOR THE TREATMENT OF B-CELL MALIGNANCIES
by: B. Aranda Orgilles, et al.
Published: (2022-06-01) -
Comparison of CD22 binding to native CD45 and synthetic oligosaccharide.
by: Bakker, T, et al.
Published: (2002) -
A novel full-human CD22-CAR T cell therapy with potent activity against CD22low B-ALL
by: Yue Tan, et al.
Published: (2021-04-01)